Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer

Enzalutamide is a second-generation anti-androgen for treatment of castration-resistant prostate cancer (CPRC). It prolongs survival of CRPC patients, but its overall survival benefit is relatively modest (4.8 months) and by 24 months most patients progress on enzalutamide. To date, however, the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingwen, Zhao, Yu, Wang, Liguo, Zhang, Jun, Karnes, R. Jeffrey, Kohli, Manish, Wang, Guixia, Huang, Haojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122410/
https://www.ncbi.nlm.nih.gov/pubmed/27221037
http://dx.doi.org/10.18632/oncotarget.9535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122410/
https://www.ncbi.nlm.nih.gov/pubmed/27221037
http://dx.doi.org/10.18632/oncotarget.9535

Ejemplares similares